Skip to main content
Signal8

Orgenesis Inc. (ORGS)

Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.

Sector: Biotechnology

Industry: Biotechnology

Orgenesis Inc. logo

Orgenesis Inc.

OTC:ORGSHealthcare
-12.00%$0.3300
CLOSED
Mkt Cap$1.71M
EV-
Float3.97M
O/S5.17M
VOL1K sh
$ Vol$405
RVOL0.71×
Inst Own1.0%
SI0.1%
Net Cash/Sh-
Dilution
Orgenesis Inc. logoOTC:ORGSClosed$0.3300-12.00%
Short interest (FINRA)
0.1%
Oct 30 (18d)

Float 3.97M · Signal8 estimate from ownership filings · Dec 4, 2024

5.3K
Oct 30 (18d)prev 5.3K– 0.0%
1.24
Oct 30 (18d)prev 1.51▼ 17.9%
Borrow (IBKR)

The cost to borrow ORGS shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
11.1%
Nov 5 (12d)prev 100.0%▼ 88.9 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20265.3K sh
Oct 15, 20265.3K sh
Sep 30, 20265.3K sh
Sep 15, 20265.3K sh
Aug 31, 20265.3K sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 5
Latest sessions
DateReported short
Nov 5, 202611.1%
Nov 4, 2026100.0%
Oct 30, 20261.6%
Oct 14, 202620.6%
3-session median 20.6%mean 40.7%range 1.6–100.0%

130 calendar days requested; 4 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for ORGS: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 5,258 ORGS shares were sold short (0.13% of a 3.97M-share float, 1.24 days to cover).